EUVIMEDEUVIMED entdecken
Crossref

Moderate Dose of Tranexamic Acid and Complications after Valvular Heart Surgery

Nikolai Hulde, Armin Zittermann, Marcus-Andre Deutsch, Vera von Dossow, Jan E Gummert, Andreas Koster

The Thoracic and Cardiovascular Surgeon · 01.04.2023 · 71 (03) · 181-188

DOI: 10.1055/s-0041-1724035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.04.2023. Verfasst von Nikolai Hulde und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Anesthesiology and Pain Therapy, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany. Hauptthemen laut MEDLINE: Tranexamic Acid, Antifibrinolytic Agents, Cardiac Surgical Procedures, Stroke. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In valvular open-heart surgery, data regarding the effect of a moderate dose of tranexamic acid (TXA) on clinical outcomes are limited.

Methods

Out of a cohort of 13,293 patients, we performed a propensity-score-matched analysis in 6,106 patients and assessed the risk of convulsive seizures (CS, primary endpoint), stroke, renal replacement therapy, and mortality (secondary endpoints). In the entire study cohort of 13,293 patients, we also assessed the multivariable-adjusted association of CS with postoperative outcomes.

Results

The risk of CS was significantly higher in the TXA group (2.4%; n = 72) than in the non-TXA group (1.0%; n = 32), with a relative risk ratio (RR) of 2.28 (95% confidence interval [CI]: 1.50–3.47; p < 0.001). The risk of CS was also higher in patients receiving TXA doses ≥25 mg/kg body weight (3.7%; n = 40) than in patients receiving 0.05). Compared with non-CS patients (n = 13,000), patients with nonhemorrhagic, nonembolic CS (n = 253) revealed higher multivariable-adjusted in-hospital risks of stroke (RR: 3.82 [95% CI: 2.44–5.60; p < 0.001]) and mortality (RR: 2.07 [95% CI: 1.23–3.48; p = 0.006]), and a higher 1-year mortality risk (RR: 1.85 [95% CI: 1.42–2.41; p < 0.001]).

Conclusion

A moderate TXA dose was associated with a significantly higher risk of seizure, but not with other clinical complications such as stroke, renal replacement therapy, and mortality. However, in the small group of patients experiencing a seizure, the risks of stroke and short- and mid-term mortality were substantially higher than in patients not experiencing a seizure, indicating that the use of a low-dose TXA protocol (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidAntifibrinolytic AgentsCardiac Surgical ProceduresStrokeHumansTreatment OutcomeSeizuresBody WeightBlood Loss, Surgical

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Institute of Anesthesiology and Pain Therapy, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany.
  • Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.

Zitieren

APA

Hulde, N., Zittermann, A., Deutsch, M. A., von Dossow, V., Gummert, J. E., & Koster, A. (2023). Moderate Dose of Tranexamic Acid and Complications after Valvular Heart Surgery. The Thoracic and Cardiovascular Surgeon, 71(03), 181-188. https://doi.org/10.1055/s-0041-1724035

Vancouver

Hulde N, Zittermann A, Deutsch MA, von Dossow V, Gummert JE, Koster A. Moderate Dose of Tranexamic Acid and Complications after Valvular Heart Surgery. The Thoracic and Cardiovascular Surgeon. 2023;71(03):181-188. doi:10.1055/s-0041-1724035

BibTeX
@article{Hulde2023,
  author = {Hulde, Nikolai and Zittermann, Armin and Deutsch, Marcus-Andre and von Dossow, Vera and Gummert, Jan E and Koster, Andreas},
  title = {Moderate Dose of Tranexamic Acid and Complications after Valvular Heart Surgery},
  journal = {The Thoracic and Cardiovascular Surgeon},
  year = {2023},
  volume = {71},
  number = {03},
  pages = {181--188},
  doi = {10.1055/s-0041-1724035}
}
Kostenlos starten →